Voss Capital’s Rocket Pharmaceuticals RCKT Stock Holding History

Voss Capital’s Portfolio RCKT Stock Details RCKT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-300,000	Closed	-$978K	–	71
2025 Q3	$978K	Sell	300,000 -200,000	-40%	-$630K	0.05%	50
2025 Q2	$1.23M	Buy	500,000 +67,760	+16%	+$343K	0.08%	47
2025 Q1	$2.88M	Buy	432,240 +10,540	+2%	+$104K	0.22%	40
2024 Q4	$5.3M	Buy	+421,700	New	+$6.35M	0.39%	33

Other funds holding RCKT

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

MAM

Monaco Asset Management Monaco $1.26B AUM 60.23% 1-Year Est. Return

Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

Voss Capital's RCKT Position: Q4 2025 in Review

Voss Capital sold out of Rocket Pharmaceuticals (RCKT) in Q4 2025, closing a stake of 300,000 shares — an estimated $978K sold.

Voss Capital first reported a position in RCKT in Q4 2024 and held it in 4 quarters. The position peaked at $5.3M in Q4 2024. 186 funds tracked by Wall St. Rank hold RCKT as of Q4 2025.

Voss Capital reported no remaining Rocket Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Voss Capital sold 300,000 Rocket Pharmaceuticals shares in Q4 2025, an estimated $978K.
Voss Capital first reported a position in Rocket Pharmaceuticals in Q4 2024 and held it in 4 quarters.
Voss Capital's Rocket Pharmaceuticals position peaked at $5.3M in Q4 2024.
186 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q4 2025.

Based on Voss Capital's 13F filing for Q4 2025, filed 13 Feb 2026.